Date of Document: May 14, 2026

CURRICULUM VITAE

Sabarinath Venniyil Radhakrishnan MD

Assistant Professor
Department of Medicine
Division of Medicine Hematology Oncology

OFFICE ADDRESS:

8701 Watertown Plank Road

Milwaukee, WI 53226

EDUCATION:

09/1996 - 01/2001 M.B.B.S, University of Kerala, Trivandrum, India
03/2001 - 03/2002 Internship, University of Kerala, Trivandrum, India
03/2003 - 03/2006 MD General Medicine, University of Kerala, Trivandrum, India

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:

07/2010 - 06/2013 Internal Medicine Residency, Internal Medicine (Program Director: Dr. Stephen Greenberg), Louisiana State University Health Sciences Center Shreveport, LA
07/2013 - 06/2017 Hematology/Oncology Fellowship, Hematology & Oncology (Program Director: Dr. Martha Glenn), Huntsman Cancer Institute/University of Utah, UT

FACULTY APPOINTMENTS:

08/2017 - 06/2019 Visiting Instructor, Medicine, Hematology & Hematologic Malignancies, University of Utah, Salt Lake City, UT
08/2019 - 06/2021 Assistant Professor, Hematology & Hematologic Malignancies, University of Utah, Salt Lake City, UT
07/2021 - Present Assistant Professor, Medicine, Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI

CENTER/INSTITUTE AFFILIATIONS:

2021 - Present Member, Discovery & Developmental Therapeutics, MCW Cancer Center, Milwaukee, WI

SPECIALTY BOARDS AND CERTIFICATION:

Board Certified	Issue Date	Expiration
Internal Medicine	10/2013	10/2023
Medical Oncology	12/2016	12/2026
Hematology	12/2016	12/2026

Licensure	Number	Issue Date	Expiration
Travancore-Cochin Medical Council (India)		2002	None
Medical License in Louisiana		2010	2013
Medical License in Utah		2013	2021
WI license		2021	2027

AWARDS AND HONORS:

2012 Abstract Achievement Award, American Society of Hematology (ASH)
2015 Joseph M Quagliana MD & Paula Quagliana Fellow Research Award, University of Utah
2017 - 2019 Pfizer Fellowship Award in Immuno-oncology Research, American Association for Cancer Research (AACR)
2022 - 2024 New Investigator Award , American Society for Transplantation and Cellular Therapy (ASTCT)

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:

American Society of Hematology (ASH) (Member)
International Myeloma Society (IMS) (Member)
American Society for Transplantation and Cellular Therapy (ASTCT) (Member)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:

Journal Review

05/2016 - Present BMC Cancer
09/2016 - Present Respiration
09/2016 - Present Hematology
10/2016 - Present Cytotherapy
01/2017 - Present Oncotarget
01/2017 - Present Biochemical Society Transactions
03/2017 - Present Journal for Immunotherapy of Cancer
03/2017 - Present Cancer Treatment Reviews
01/2021 - Present Journal of Clinical Medicine
04/2021 - Present Scientific Reports
04/2021 - Present Annals of Medicine
03/2024 - Present Blood
03/2024 - Present Transplantation and Cellular Therapy

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:

2025 Reviewer, Abstract Review Committee, American Society of Hematology

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:

Active

Non-Peer Review

Title:	Start up grant
Source:	Medical College of Wisconsin
Role & Effort:	Principal Investigator
PI:	Sabarinath Venniyil Radhakrishnan
Dates:	07/01/2021 - 06/30/2026
Direct Funds:	$550,000

Prior

Peer Review

Title:	Chimeric antigen receptor (CAR) T cell therapy for multiple myeloma
Source:	American Association for Cancer Research
Role & Effort:	Principal Investigator
PI:	Radhakrishnan, Sabarinath
Dates:	08/2017 - 07/2019
Direct Funds:	$110,000
Title:	BCMA targeted CAR T cells armored with a mechanism to block the “Don’t Eat me” pathway in macrophages.

Source: Paula & Rodger Riney Foundation grant
Role & Effort: Principal Investigator
PI: Radhakrishnan, Sabarinath
Dates: 06/15/2022 - 06/14/2024
Direct Funds: $1,120,193

Title: Targeting trogocytosis pathway to overcome CAR T cell failure in Multiple Myeloma
Source: American Society for Transplantation and Cellular Therapy (ASTCT)
Role & Effort: Principal Investigator
PI: Radhakrishnan, Sabarinath
Dates: 07/2022 - 06/2024
Direct Funds: $100,000 (New Investigator Award)

Non-Peer Review

Title: Chimeric Antigen Receptor T cells targeting CD229: A new treatment modality for multiple myeloma
Source: Quagliana Fellow Research Award, University of Utah
Role & Effort: Fellow
Dates: 07/2015 - 06/2016
Direct Funds: $10,000

Title: Development of a high affinity antibody against CD229 for the treatment of Multiple Myeloma
Source: American Cancer Society
Role & Effort: Principal Investigator
PI: Radhakrishnan, Sabarinath
Dates: 01/2019 - 06/2020
Direct Funds: $30,000 (Institutional Research Grant)

Title: Development of an antibody drug conjugate targeting CD229 for the treatment of Multiple Myeloma
Source: Huntsman Cancer Institute
Role & Effort: Principal Investigator
PI: Radhakrishnan, Sabarinath
Dates: 07/2019 - 06/2021
Direct Funds: $60,000 (Cancer Center Support grant, Experimental Therapeutics)

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:

International

A high throughput process for generation and characterization of functional chimeric antigen receptors against novel targets, University of Wurzburg, 03/2017

Cancer Immunotherapy: Chimeric Antigen Receptor T cells., Seminar on Virology & Immunology, Trivandrum Medical College Platinum Jubilee, Kerala, India, 08/2022

Cellular therapies in multiple myeloma., International Conference on Multidisciplinary Management of Common Cancers, Cancer Control & Research Society, Kerala, India, 03/08/2024

Local

A novel CAR T cell therapy for multiple myeloma., Immunology, Inflammation & Infectious Disease

Summer symposium, Park City, Utah,, 08/2017

Evolving landscape of AL amyloid, 5th Annual Controversies in Hematologic Malignancies Symposium, Milwaukee, WI, 2026

COMMITTEE SERVICE:

Medical College of Wisconsin

2021 Member, Fellowship application review, Hematology & Oncology, Medicine, MCW

2022 Reviewer, Cancer Center Fellowship program

2023 Reviewer, Research proposal review panel, Hematology, Oncology & Bone marrow transplant, Pediatrics

2026 Reviewer, Cancer Center Fellowship

LINK TO LAB WEBSITE:

https://www.mcw.edu/departments/medicine/divisions/hematology-oncology-cancer/research/radhakrishnan-laboratory

BIBLIOGRAPHY

Refereed Journal Publications/Original Papers

1. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, Al Hadidi S, **Radhakrishnan SV**, Narra R, Bhutani D, Thanendrarajan S, Janz S, Zangari M, Lentzsch S, Van Rhee F, Crescencio JCR, D'Souza A, Chakraborty R, Mohan M, Schinke C. Haematologica. 2023 Aug 31.
2. Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity. Vander Mause ER, Baker JM, Dietze KA, **Radhakrishnan SV**, Iraguha T, Omili D, Davis P, Chidester SL, Modzelewska K, Panse J, Marvin JE, Olson ML, Steinbach M, Ng DP, Lim CS, Atanackovic D, Luetkens T. Sci Transl Med. 2023 Jul 19;15(705)
3. Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience. Mohan M, Rein LE, Thalambedu N, Ogunsesan Y, Hussain M, Sethi J, Khan F, Gundarlapalli S, Yarlagadda L, Dhakal B, Price M, Shirey M, Warner D, Thanendrarajan S, Janz S, **Radhakrishnan SV**, Al Hadidi S, Szabo A, D'Souza A, Zangari M, van Rhee F, Chhabra S, Schinke C. Am J Hematol. 2022 Dec;97(12):E451-E453.
4. Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion. Olson M, Vander Mause E, **Radhakrishnan SV**, Brody JD, Rapoport AP, Welm AL, Atanackovic D, Luetkens T. Leukemia. 2022 Jul;36(7):1943-1946.
5. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, **Radhakrishnan SV**, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C. Am J Hematol. 2022 Jul;97(7):E276-E280.
6. Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. Mohan M, Nagavally S, Dhakal B, **Radhakrishnan SV**, Chhabra S, D'Souza A, Hari P. Blood Adv. 2022 Apr 26;6(8):2466-2470.
7. The Prolyl Hydroxylase Inhibitor Dimethyl Oxalyl Glycine Decreases Early Gastrointestinal GVHD in Experimental Allogeneic Hematopoietic Cell Transplantation. Palaniyandi S, Kumari R, **Radhakrishnan SV**, Strattan E, Hakim N, Munker M, Kesler MV, Hildebrandt GC. Transplantation. 2020 Jun 29.
8. CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. **Radhakrishnan SV**, Luetkens T, Scherer SD, Davis P, Vander Mause ER , Olson M, Yousef S, Panse J, Abdiche Y, Li KD, Miles RR, Matsui W, Welm AL, Atanackovic D. Nat Commun. 2020 Feb 7;11(1):798.
9. In Vivo Vaccination Effect in Multiple Myeloma Patients Treated with the Monoclonal Antibody Isatuximab. Atanackovic D, Yousef S, Shorter C, Tantravahi SK, Steinbach M, Iglesias F, Sborov D,

Radhakrishnan SV, Chiron M, Miles R, Salama M, Kröger N, Luetkens T. Leukemia. 2020 Jan;34(1):317-321.
10. A phase 1 study of intravenous busulfan as a conditioning regimen for Multiple Myeloma. **Radhakrishnan SV**, Boyer M, Sherwin CM, Zangari M, Tricot GJ. Cell Transplant. 2019 Dec;28(12):1624-1631.
11. Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/ NFKB/MAPK activation. Templin J, Atanackovic D, Hasche D, **Radhakrishnan SV**, Luetkens T. Oncotarget. 2017 Jul 25;8(30):49253-49263
12. Preventive azithromycin treatment reduces noninfectious lung injury and acute graft versus host disease in a murine model of allogeneic hematopoietic cell transplantation. **Radhakrishnan SV**, Palaniyandi S, Mueller G, Miklos S, Hager M, Spacenko E, Karlsson FJ, Huber E, Kittan NA, Hildebrandt GC. Biol Blood Marrow Transplant. 2015 Jan;21(1):30-8.
13. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. Schwab L, Goroncy L, Palaniyandi S, Gautam S, Triantafyllopoulou A, Mocsai A, Reichardt W, Karlsson FJ, **Radhakrishnan SV**, Hanke K, Schmitt-Graeff A, Freudenberg M, von Loewenich FD, Wolf P, Leonhardt F, Baxan N, Pfeifer D, Schmah O, Schönle A, Martin SF, Mertelsmann R, Duyster J, Finke J, Prinz M, Henneke P, Häcker H, Hildebrandt GC, Häcker G, Zeiser R. Nat Med. 2014 Jun;20(6):648-54.
14. Murine cytomegalovirus immediate-early 1 gene expression correlates with increased GVHD after allogeneic hematopoietic cell transplantation in recipients reactivating from latent infection. Palaniyandi S, **Radhakrishnan SV**, Karlsson FJ, Stokes KY, Kittan N, Huber E, Hildebrandt GC. PLoS One. 2013 Apr 15;8(4).
15. Beneficiary Effect of Autologous Hematopoietic Cell Transplantation in Idiopathic Ulcerative Dermatitis C57BL/6 Mice. Palaniyandi S, Huber E, **Radhakrishnan SV**, Orchard EA, Hildebrandt GC. J Bone Marrow Res. 2: 139
16. Palaniyandi S, **Radhakrishnan SV**, Karlsson FJ, Stokes KY, Kittan N, Huber E, Hildebrandt GC. Murine cytomegalovirus immediate-early 1 gene expression correlates with increased GVHD after allogeneic hematopoietic cell transplantation in recipients reactivating from latent infection. PLoS One. 2013;8(4):e61841. PMCID: PMC3626592
17. Schwab L, Goroncy L, Palaniyandi S, Gautam S, Triantafyllopoulou A, Mocsai A, Reichardt W, Karlsson FJ, **Radhakrishnan SV**, Hanke K, Schmitt-Graeff A, Freudenberg M, von Loewenich FD, Wolf P, Leonhardt F, Baxan N, Pfeifer D, Schmah O, Schönle A, Martin SF, Mertelsmann R, Duyster J, Finke J, Prinz M, Henneke P, Häcker H, Hildebrandt GC, Häcker G, Zeiser R. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. Nat Med. 2014 Jun;20(6):648-54.
18. **Radhakrishnan SV**, Palaniyandi S, Mueller G, Miklos S, Hager M, Spacenko E, Karlsson FJ, Huber E, Kittan NA, Hildebrandt GC. Preventive azithromycin treatment reduces noninfectious lung injury and acute graft-versus-host disease in a murine model of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015 Jan;21(1):30-8.
19. Templin J, Atanackovic D, Hasche D, **Radhakrishnan SV**, Luetkens T. Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation. Oncotarget. 2017 Jul 25;8(30):49253-49263. PMCID: PMC5564765
20. Atanackovic D, Yousef S, Shorter C, Tantravahi SK, Steinbach M, Iglesias F, Sborov D, **Radhakrishnan SV**, Chiron M, Miles R, Salama M, Kröger N, Luetkens T. In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. Leukemia. 2020 Jan;34(1):317-321.
21. **Radhakrishnan SV**, Boyer M, Sherwin CM, Zangari M, Tricot G. A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma. Cell Transplant. 2019 Dec;28(12):1624-1631. PMCID: PMC6923548
22. **Radhakrishnan SV**, Luetkens T, Scherer SD, Davis P, Vander Mause ER, Olson ML, Yousef S, Panse J, Abdiche Y, Li KD, Miles RR, Matsui W, Welm AL, Atanackovic D. CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. Nat Commun. 2020 Feb 07;11(1):798. PMCID: PMC7005855
23. Palaniyandi S, Kumari R, Venniyil Radhakrishnan S, Strattan E, Hakim N, Munker R, Kesler MV, Hildebrandt GC. The Prolyl Hydroxylase Inhibitor Dimethyl Oxalyl Glycine Decreases Early Gastrointestinal GVHD in Experimental Allogeneic Hematopoietic Cell Transplantation. Transplantation. 2020 Dec;104(12):2507-2515. PMCID: PMC8139022
24. Mohan M, Nagavally S, Dhakal B, **Radhakrishnan SV**, Chhabra S, D'Souza A, Hari P. Risk of infections

with B-cell maturation antigen-directed immunotherapy in multiple myeloma. Blood Adv. 2022 Apr 26;6(8):2466-2470. PMCID: PMC9043928

25. Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, **Radhakrishnan SV**, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. Am J Hematol. 2022 Jul;97(7):E276-E280. PMCID: PMC10476149
26. Olson ML, Mause ERV, **Radhakrishnan SV**, Brody JD, Rapoport AP, Welm AL, Atanackovic D, Luetkens T. Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion. Leukemia. 2022 Jul;36(7):1943-1946. PMCID: PMC9252916
27. Olson ML, Mause ERV, **Radhakrishnan SV**, Brody JD, Rapoport AP, Welm AL, Atanackovic D, Luetkens T. Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion Leukemia. July 2022;36(7):1943-1946.
28. Mohan M, Rein LE, Thalambedu N, Ogunsesan Y, Hussain M, Sethi J, Khan F, Gundarlapalli S, Yarlagadda L, Dhakal B, Price M, Shirey M, Warner D, Thanendrarajan S, Janz S, **Radhakrishnan SV**, Al Hadidi S, Szabo A, D'Souza A, Zangari M, van Rhee F, Chhabra S, Schinke C. Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience. Am J Hematol. 2022 Dec;97(12):E451-E453.
29. Al Hadidi S, Szabo A, Esselmann J, Hammons L, Hussain M, Ogunsesan Y, Thalambedu N, Khan F, Sethi J, Janardan A, **Radhakrishnan SV**, Thanendrarajan S, Schinke C, Dhakal B, Janz S, Chhabra S, D'Souza A, Zangari M, van Rhee F, Mohan M. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. Bone Marrow Transplant. 2023 Apr;58(4):443-445.
30. Vander Mause ER, Baker JM, Dietze KA, **Radhakrishnan SV**, Iraguha T, Omili D, Davis P, Chidester SL, Modzelewska K, Panse J, Marvin JE, Olson ML, Steinbach M, Ng DP, Lim CS, Atanackovic D, Luetkens T. Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity. Sci Transl Med. 2023 Jul 19;15(705):eadd7900.
31. Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, Al Hadidi S, **Radhakrishnan SV**, Narra R, Bhutani D, Thanendrarajan S, Janz S, Zangari M, Lentzsch S, Van Rhee F, Crescencio JCR, D'Souza A, Chakraborty R, Mohan M, Schinke C. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2024 Mar 01;109(3):906-914. PMCID: PMC10905074
32. Mohan M, Kothari A, Verhagen N, Shreenivas A, **Radhakrishnan SV**, Dhakal B, Figueroa-Castro C, Chhabra S, Janz S, Pasquini M, Hamadani M, Szabo A, D'Souza A, N3C consortium. Blood and marrow transplant within 4 weeks of SARS-CoV-2 infection is associated with increased risk of mortality: a National COVID Cohort Collaborative (N3C) Study. Bone Marrow Transplant. 2024 Jan;59(1):121-124.
33. Hammons L, Haider S, Portuguese AJ, Banerjee R, Szabo A, Pasquini M, Chhabra S, Radhakrishnan S, Mohan M, Narra R, Dong J, Janz S, Shah NN, Hamadani M, D'Souza A, Hari P, Dhakal B. Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation. Br J Haematol. 2024 Mar;204(3):887-891.
34. Mohan M, Szabo A, Patwari A, Esselmann J, Patel T, Bachu R, Rein LE, Janardan A, Bhatlapenumarthi V, Annyapu E, Skoog C, Goff A, Hadidi SA, **Radhakrishnan SV**, Thanendrarajan S, Zangari M, Shah N, van Rhee F, Dhakal B, Hamadani M, D'Souza A, Schinke C. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. Bone Marrow Transplant. 2024 May;59(5):647-652.
35. Morales EA, Dietze KA, Baker JM, Wang A, Avila SV, Iglesias F, **Radhakrishnan SV**, Mause EV, Olson ML, Sun W, Rosati E, Chidester SL, Iraguha T, Fan X, Atanackovic D, Luetkens T. Restricting CAR T Cell Trafficking Expands Targetable Antigen Space. bioRxiv. 2024 Feb 11. PMCID: PMC10871312
36. Gong Z, Umoru G, Monge J, Shah N, Mohyuddin GR, **Radhakrishnan SV**, Chakraborty R, Rasche L, Schinke C, D'Souza A, Mohan M. Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study. Blood Cancer J. 2024 Mar 05;14(1):36.

PMCID: PMC10914796

37. Dietze KA, Nguyen K, Pathni A, Fazekas F, Sun W, Rosati E, Baker JM, Figueroa MG, Gebru E, Yamoah D, Mulatu R, Wang A, Rapoport AP, Lum D, Fan X, **Radhakrishnan SV**, Atanackovic D, Upadhyaya A, Luetkens T. Preventing trogocytosis by cathepsin B inhibition augments CAR T cell function. bioRxiv. 2025 Sep 04. PMCID: PMC11195252
38. Chunara F, Lugo C, Osinski K, Shah MR, Shah N, Kent J, Mohyuddin GR, **Radhakrishnan SV**, Kaur G, Chakraborty R, Banerjee R, Rasche L, Schinke C, D'Souza A, Szabo A, Mohan M. Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients. Blood Cancer J. 2025 Apr 08;15(1):61. PMCID: PMC11979001
39. Mohan M, Danziger N, Akhtar OS, Narra R, Pasquini MC, Radhakrishnan S, Dhakal B, D'Souza A, Lin D, Ho C, Kurzrock R. Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability. Blood Adv. 2026 Feb 24;10(4):1400-1404. PMCID: PMC12927052

Books, Chapters, and Reviews

1. Red cell destruction disorders: Hematology Board Review: Blueprint Study Guide and Q&A. **Radhakrishnan SV** and Parker CJ, May 2018
2. Chronic graft versus host disease: Clinical Manual of Blood and Bone Marrow Transplantation. **Radhakrishnan SV** and Couriel DR, June 2017
3. **Radhakrishnan SV**, Hildebrandt GC. A call to arms: a critical need for interventions to limit pulmonary toxicity in the stem cell transplantation patient population. Curr Hematol Malig Rep. 2015 Mar;10(1):8-17.
4. Atanackovic D, **Radhakrishnan SV**, Bhardwaj N, Luetkens T. Chimeric Antigen Receptor (CAR) therapy for multiple myeloma. Br J Haematol. 2016 Mar;172(5):685-98.
5. Atanackovic D, Steinbach M, **Radhakrishnan SV**, Luetkens T. Immunotherapies targeting CD38 in Multiple Myeloma. Oncoimmunology. 2016;5(11):e1217374. PMCID: PMC5139636
6. **Radhakrishnan SV**, Couriel DR. Diagnosis and treatment of chronic graft?versus?host disease Clinical Manual of Blood and Bone Marrow Transplantation. 1 January 2017:334-347.
7. Luetkens T, Yousef S, **Radhakrishnan SV**, Atanackovic D. Current Strategies for the Immunotherapy of Multiple Myeloma. Oncology (Williston Park). 2017 Jan 15;31(1):55-63.
8. **Radhakrishnan SV**, Bhardwaj N, Steinbach M, Weidner J, Luetkens T, Atanackovic D. Elotuzumab as a novel anti-myeloma immunotherapy. Hum Vaccin Immunother. 2017 Aug 03;13(8):1751-1757. PMCID: PMC5557243
9. **Radhakrishnan SV**, Bhardwaj N, Luetkens T, Atanackovic D. Novel anti-myeloma immunotherapies targeting the SLAM family of receptors. Oncoimmunology. 2017;6(5):e1308618. PMCID: PMC5468000
10. Olson M, **Radhakrishnan SV**, Luetkens T, Atanackovic D. The role of surface molecule CD229 in Multiple Myeloma. Clin Immunol. 2019 Jul;204:69-73.
11. Mohan M, Radhakrishnan S, Schinke C, Katodritou E, Fonseca R. Reassessing the Duration of Induction Therapy for Newly Diagnosed, Transplant-Eligible Myeloma Patients in the Context of Quadruple CD38 Monoclonal Antibody-Based Regimens: Is 24 Weeks Optimal? Am J Hematol. 2026 May;101(5):1141-1147.

Non-Refereed Journal Publications/Original Papers

1. The role of surface molecule CD229 in Multiple Myeloma. Olson M, **Radhakrishnan SV**, Luetkens T, Atanackovic D. Clin Immunol. 2018 Oct 13. pii: S1521-6616
2. Elotuzumab as a Novel Anti-Myeloma Immunotherapy. **Radhakrishnan SV**, Bhardwaj N, Steinbach M, Weidner J, Luetkens T, Atanackovic D. Human Vaccines and Immunotherapeutics. Volume 13, issue 8, May 2017
3. Novel anti-myeloma immunotherapies targeting the SLAM family of receptors. **Radhakrishnan SV**, Bhardwaj N, Luetkens T, Atanackovic D. Oncoimmunology. 2017 Mar 28;6(5):e1308618
4. Coinhibitory molecule PD-1 as a therapeutic target in the microenvironment of Multiple Myeloma. Atanackovic D, Luetkens T, Radhakrishnan S, Kroeger N, Current Cancer Drug Targets. 2017;17(9):839-845
5. Current Strategies for the Immunotherapy of Multiple Myeloma. Luetkens T, Yousef S, **Radhakrishnan SV**, Atanackovic D. Oncology (Williston Park). 2017 Jan 15;31(1).
6. Immunotherapies targeting CD38 in Multiple Myeloma. Atanackovic D, Steinbach M, **Radhakrishnan SV**, Luetkens T. Oncoimmunology. 2016 Aug 5;5(11).

7. Chimeric Antigen Receptor (CAR) therapy for multiple myeloma. Atanackovic D, **Radhakrishnan SV**, Bhardwaj N, Luetkens T. Br J Haematol 2016 Mar 20;172(5):685-98
8. Pomalidomide as Consolidation Therapy after Salvage Autologous Stem Cell Transplant. Steinbach M, Luetkens T, Vinik K, **Radhakrishnan SV** , Atanackovic D. J J Bone Stem Res. 2016, 2(2): 015
9. A call to arms: a critical need for interventions to limit pulmonary toxicity in the stem cell transplantation patient population. **Radhakrishnan SV** and Hildebrandt GC. Curr Hematol Malig Rep. 2015 Mar;10(1):8-17

Abstracts

1. PI3 kinase inhibition reduces CAR T cell trogocytosis mediated fratricide, American Society of Hematology (ASH) Annual Meeting, Orlando, December 2025
2. CD47-CD138 bispecific antibody exhibits selective targeting of multiple myeloma. American Society of Hematology (ASH) annual meeting, San Diego, December 2024
3. PI3 Kinase Pathway Regulates CAR T Cell Trogocytosis American Society of Hematology (ASH) annual meeting, San Diego, December 2024
4. CD229-targeted CAR T cell therapy for the treatment of B cell lymphoma. American Association of Cancer Research (AACR) annual meeting, Philadelphia, April 2020
5. Dimethyl Oxalyl Glycine a Prolyl Hydroxylase Inhibitor Decreases Early Gastrointestinal Gvhd Via Two Independent Pathways of Apoptosis after Allogeneic Hematopoietic Cell Transplantation. American Society of Hematology (ASH) annual meeting, San Diego, December 2018
6. Chimeric Antigen Receptor (CAR) T Cells Specific for CD229: A Potentially Curative Approach for Multiple Myeloma. American Society of Hematology (ASH) annual meeting, Atlanta, December 2017
7. A Novel High Throughput Process for Generation and Characterization of Chimeric Antigen Receptor (CAR) T Cells. Society of Hematologic Oncology (SOHO) annual meeting, Houston, September 2017
8. A high-throughput process for the development and characterization of chimeric antigen receptors (CARs). American Association of Cancer Research (AACR) annual meeting, Washington DC, April 2017
9. Rapid Process for the Generation of Functional Chimeric Antigen Receptors Against Novel Targets. European Society for Blood and Marrow Transplantation (EBMT) annual meeting, Marseilles, March 2017
10. Azithromycin induces the expansion of regulatory T cells and diminishes allo reactive T cell proliferation in vitro and in vivo. American Society for Blood and Marrow Transplantation (ASBMT) annual meeting, Salt Lake City, February 2013
11. The Prolyl Hydroxylase Inhibitor Dimethyl Oxalyl Glycine Decreases the Severity of Acute Lung Injury after Allogeneic Hematopoietic Cell Transplantation. American Society of Hematology (ASH) annual meeting, Atlanta, December 2012
12. Mediation of LA-4 lung epithelial cell injury by allo reactive donor T cells. American Society for Clinical Oncology (ASCO), annual meeting, Chicago, June 2011

Patents

1. Compositions that target CD47 and CD138 and methods of making and using the same. Inventors: **Radhakrishnan SV**, Figueroa MG. U.S. Provisional Application No. 63/715,115. Filed Nov1, 2024
2. Self-Regulated Chimeric Antigen Receptor T cells and Methods of Preparing and using the same. Inventor: **Radhakrishnan SV**. U.S. Provisional Application No. 63/643,548. Filed May 7, 2024
3. CD229 CAR T Cells and Methods of Use Thereof. Luetkens T, Atanackovic D, **Radhakrishnan SV** (Published). Patent No.WO2018017708A1. 01/25/2018